DPYSL2 and colorectal carcinoma: Our results not only verify that CRMP2 is a CRC tumor marker [15] but provide molecular evidence supporting CRC and diabetes comorbidity, as well as the involvement of glucose in CRC disease progression via mediating the CRMP2-regulated cytoskeleton.